J&J's Momenta calls infringement against Viatris' Copaxone generic, but why now?

Johnson & Johnson’s Momenta Pharmaceuticals unit is crying patent infringement against Mylan—now Viatris—plus two of the generics maker’s Indian manufacturing partners, according to a new lawsuit. But the generic drug they're targeting is five years old.